Dr. Erik Cornel

Uroloog
Dr. Erik Cornel is Uroloog bij Andros Clinics

Dr. Erik Cornel (BIG 79020503601) werkt tevens als uroloog bij het ZGT in Hengelo en Almelo. Zijn opleiding geneeskunde volgde hij aan de universiteit van  In Nijmegen promoveerde hij op “Magnetic Resonance Spectroscopy in Urological Oncology”.

Zoek, vind en waardeer zorgaanbieders op ZorgkaartNederland.nl
Patientenfederatie Nederland
Gemiddelde waarderingen op ZorgkaartNederland: 9.7

Cornel, E.B. Bekijk 15 waarderingen

Uitgebreid CV

Werkervaring

2023 – heden Uroloog, Andros Clinics
2000 – heden Uroloog, Ziekenhuis Groep Twente (ZGT), Hengelo en Almelo
1999 – 2000 Uroloog in opleiding, Rijnstate Hospital, Arnhem
1997 – 1998 Uroloog in opleiding, Radboudumc, Nijmegen
1996 – 1997 Uroloog in opleiding, Canisius Wilhelmina Ziekenhuis (CWZ), Nijmegen
1994 – 1995 Chirurg in opleiding, Deventer Ziekenhuis

Opleiding

Promotie urologie, Raboud Universiteit Nijmegen
‘Magnetic Resonance Spectroscopy in Urological Oncology’
Studie Geneeskunde, Rijksuniversiteit Groningen

Lidmaatschappen

2002 – heden International member American Urology Association
2000 – heden Fellow of the European Board of Urology
2000 – heden Member Dutch Urological Association (NVU)
2000 – heden Member European Association of Urology (EAU)

Overige functies

Clinical Trial

2021 – heden Investigator “beter gezond” trial
2021 – 2022 Investigator “Evaluatie endoscopische inschatting invasiviteit blaastumoren”

Onderzoek

2018 – 2020 Investigator REBACARE trial
2016 – 2019 Investigator decision aid castration resistent prostate cancer
2016 – 2017 Investigator EPICHECK trial
2016 – 2017 Principal Investigator OPSYS trial
2015 – 2017 Investigator KWF / Alpe duZes 4M trial
2013 – 2016 Investigator decision aid newly diagnosed prostate cancer
2012 – 2016 Investigator multicentre biomarker study prostate cancer NG12.01
2012 – 2014 Investigator bicentric MRI guide focal laser ablation study
2011 – 2015 Investigator bicentric MRI guide focal cryo therapy study
2011 – 2015 Investigator bicentric Aribca Study
2011 – 2013 Investigator IMPACT Study
2010 – 2013 Investigator multicentric Phase 1 Telomerix bladder cancer study
2009 – 2012 Investigator multicentre biomarker study prostate cancer NG09.01
2008 – 2011 Investigator ARTS study
2006 – 2011 Principal Country Investigator fase IIIB ICELAND study
2006 – 2009 Investigator fase 3 multicentric Eoquin II trial
2006 – 2008 Investigator SURVIN: bicentric KWF funded Bladder Cancer Marker Dutch study
2005 – 2007 Principal Country Investigator: Omnic Ocas Nycturia study
2004 – 2009 Investigator Reduce Trial
2004 – 2007 Investigator DD3/PCA3 KWF funded multicentric Dutch study

11-10-‘21 GCP-WMO re-registration
08-12-‘17 BROK certification Good Clinical Practice
20-08-‘14 Recertification Good Clinical Practice
07-05-‘12 Recertification Good Clinical Practice
11-03-‘08 Good Clinical Practice course

Clinical Teaching

2015 – Teacher urology operation assistent Saxion Hogeschool, Enschede
2010 – Teacher uro-oncology oncology nurse, CIVO (Centraal Instituut voor Verpleegkundig Onderwijs) Hengelo
2015 – 2022 Scientific board ASCO-GU direct
2000 – 2018 Several times per year instructor / speaker Dutch post graduate training meetings

Overig

2016 – 2021 Board member Convent van Hoogleraren en Wetenschappers of Dutch Urological Society
2016 – 2020 Substitute NVU member Raad van Wetenschap & Innovatie Federatie Medisch Specialisten
2014 – 2020 Member scientific committee of ZGT
2014 – 2019 Member calamity committee of ZGT
2011 – 2019 Member scientific committee of Dutch Urological Society
2016 – 2017 Member scientific committee dutch guidelines male incontinence
2014 – 2017 Member oncology work group of Dutch Urological Society
2012 – 2017 Chairman uro-oncology committee ZGT / MS

Publicaties

3-D and 2-D reconstruction of bladders for the assessment of inter-session detection of tissue changes: a proof of concept. Groenhuis V, de Groot AG, Cornel EB, Stramigioli S, Siepel FJ.Int J Comput Assist Radiol Surg. 2023 Apr 21. doi: 10.1007/s11548-023-02900-7. Online ahead of print.

Selecting interventions for a psychosocial support program for prostate cancer patients undergoing active surveillance: a modified Delphi study. Donachie K, Adriaansen M, Nieuwboer M, Cornel E, Bakker E, Lechner L. Psycho-Oncology. 2022:; 31; 2132-2140.

What interventions affect the psychosocial burden experienced by prostate cancer patients undergoing active surveillance? A scoping review. Support Care Cancer, 2022 June; 30(6):4699-4709.

Clinical use of the SelectMDx urinary biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1110-1119.

Verbetering van continentie door urethrasparende robot geassisteerde laparoscopische prostatectomie. Tijdschr Urol, (2021) 11:62/67

Re: Outcomes of a Noninferiority Randomised Controlled Trial of Surgery for Men with Urodynamic Stress Incontinence After Prostate Surgery (MASTER). Casteleijn NF and Cornel EB. Eur Urol. 2021 Jun;79(6):e180-e181. doi:10.1016/j.eururo.2021.03.012.

Argus-T adjustable male sling: a three year follow-up study on urinary incontinence and patient’s satisfaction. Neurourol Urodyn. 2021 Mar;40(3):802-809. doi: 10.1002/nau.24619.

Optimizing the risk threshold of lymph node involvement for performing extended pelvic lymph node dissection in prostate cancer patients: a cost-effectiveness analysis. Urol Oncol. 2021 Jan;39(1):72.e7-72.e14. doi: 10.1016/j.urolonc.2020.09.014.

No need to say goodbye to transrectal biopsies in the diagnostic work-up for prostate cancer. World J Urol. 2021 Oct;39(10):4007-4008.

Optimizing psychosocial support in prostate cancer patients during asctive surveillance. Int J Urol Nurs, 2020:14; 115-123

Development and usability testing of a multi-criteria value clarification methods for patients with localized prostate cancer. Health Infomatics J. 2020 Mar; 26(1):486-498

The usefullness of the modified frailty index for muscle-invasive bladder cancer patients treated with radical cystectomy. Curr Urology. 2020 Mar;14(1):32-37

Focal Salvage MR imaging guided Cryo ablation for localized prostate cancer recurrence after radiotherapy: 12 month follow up. J Vasc Interv Radiol. 2020 Jan; 31(1): 35-41

High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naïve: the next step in magnetic resonance imaging accessibility. Eur Urol. 2019 Nov;76(5):574-581

Head-to-head comparison of transrectal ultrasound guided prostate biopsy versus multi-parametric prostate resonance imaging with subsequent MR-guided biopsy in biopsy-naïve men with elevated PSA; a large prospective multicenter clinical study. Eur Urol. 2019 apr; 75(4): 570-579

Injectable Bulking Agent to Treat Post Prostatectomy Urinary Incontinence: A Safety and Effectiveness Pilot Study. Biomed Res Int. 2018 Dec 6;201, https://10.1155/2018/2796967

External validation of prediction models predicting the probability of lymph node involvement in prostate cancer patients. Eur Urol Oncol. 2018 Oct;1(5):411-417.

Witjes JA, Morote J, Cornel EB, Gakis G, van Valenberg FJP, Lozano F, Sternberg JA, Willemsen e, Hegemann ML, Paitan Y, Leibovitch I. Performance of the bladder epichec methylation test for patients under surveillance for non-mucle-invasieve bladder cancer: results of a multicenter, prospective blinded clinical trial. Eur Urol Oncol. 2018 Sep;1(4):307-313.

van Doeveren T, van Leeuwen PJ, Aben KKH, van der Aa M, Barendrecht M, Boevé ER, Cornel EB, van der Heijden AG, Hendricksen K, Hirdes W, Kooistra A, Kroon B, Leliveld AM, Meijer RP, van Melick H, Merks B, de Reijke TM, de Vries P, Wymenga LFA, Wijsman B, Boormans JL. Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial. Contemp Clin Trials Commun. 2018 Feb 28;9:121-129. doi: 10.1016/j.conctc.2018.01.007. eCollection 2018 Mar.

The impact of prostate cancer diagnosis and treament decisionmaking on health-related quality of life before treatment onset. Support Care Cancer. 2018 Apr;26(4):1297-1304

Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. The Journal of Urology 2017; 198(5): 1054 -1060.

MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: Correlation of treatment effects with imaging. World J Urol. 2017 May; 35(5): 703 -711.

The effect of office based flexible and rigid cystoscopy on pain experience in female patients.  Investig Clin Urol. 2017 Jan; 58(1): 48-53.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker–Based Risk Score. Eur Urol. 2016 Nov; 70(5): 740-748

Validatie van een nieuwe urinetest voor klinische significante prostaatkanker. Tijdschrift voor Urologie, 2016 vol 6: 34-43.

MR targeted TRUS prostate biopsy using local reference augmentation – initial experience. Int Urol Nephrol, 2016 Jul; 48(7): 1037- 45.

Argus-T adjustable male sling: the influence of surgical technique on complications and short-term efficacy. Urol Int. 2016; 96(2): 164 -70.

Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomized study (ICELAND). Eur Urol, 2016, Apr; 69(4): 720-727-603.

Identification of a candidate gene panel for early diagnosis of prostate cancer. Clin Cancer Res. 2015 Jul 1;21(13):3061-70.

Waarde van het multidisciplinair uro-oncologisch overleg. NtVG 2015;159:A8590

Het niet-spierinvasieve blaascarcinoom: een retrospectieve kwaliteitscontrolestudie Tijdschrift voor Urologie, 8 (2014), 178-184

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014, 65, 534-542

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with non-muscle invasive bladder cancer. J Urol. 2013 Jun;189(6):2077-82.

Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study.  Eur Urol. 2013, Apr;63(4):597-603.

Case report. Epidermoide cyste van de testis. Tijdschrift voor Urologie, 2 (2012), 6; 135

RE: EURUROL-D-12-00058 Letter to the Editor of European Urology Concerning: Contemporary role of androgen deprivation therapy for prostate cancer Eur urol 61 (2012) 11-25 Pagliarulo et al. Cornel E.B. 2012 Feb 25.

Phase 2 study of adjuvant intravesical instillations of apaziquone in high-risk non-muscle invasive bladder cancer J Urol. 2012 April;187:1195

Letter to the Editor of European Urology Concerning: Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling European urology 58 (2010) 767-772. Cornel E.B. European Urology 59 (2011), p. e12 DOI information: 10.1016/j.eururo.2010.11.045

Letter to the Editor of European Urology: The REDUCE Trial. Cornel E.B European Urology 59 (2011), p. e1

Letter to the Editor of British Journal Urology Concerning: Surgery illustrated- surgical atlas Transurethral resection of bladder tumours. Cornel E.B BJU int 2010 Oct;106(8):1237

Letter to the Editor of British Journal Urology Concerning; The 1-year outcome of the transobturator retroluminal repositioning sling in the treatment of male stress urinary incontinence. Elzevier H.W. and Cornel E.B. BJU int 2010 Oct;106(7):1091

Re: Can AdVance transobturator sling suspension cure male urinary postoperative stress incontinence? Urol. 2010 Sep;184(3):1229

Re: Can Advance Transobturator Sling Suspension Cure Male Urinary Postoperative Stress Incontinence? E. B. Cornel, H. W. Elzevier and H. PutterJ Urol 2010; 183: 1459-1463. [Epub ahead of print] No abstract available. PMID: 20728906

Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1192-202.

Can Advance Transobturator Sling Suspension cure Male Urinary post operative Stress incontinence? J Urol. 2010 Apr;183(4):1459-63.

Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int. 2010 Apr;105(7):956-62. Epub 2009 Oct 8.

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol. 2009 Jun;27(3):337-42.

Allelic imbalance analysis using a single nucleotide polymorphism microarray for the detection of bladder cancer recurrence. Clin Cancer Res. 2008 Dec 15;14(24):8198-204.

Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet. 2008 Nov;40(11):1307-12.

The effect on pain experience for male patients of watching their own office based flexible cystoscopy. BJU Int. 2008 Nov;102(10):1445-6.

Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008 Jul;62(7):1076-86.

Detection of TMPRSS2-ERG fusion transcripts and PCA3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007 Clin Cancer Res. 2007 sept 1;13(17):5103-5108.

Molecular PCA3 diagnostics on prostatic fluid. The Prostate. 2007 Apr;67:881-887.

Re: Rufus Cartwright and Linda Cardozo. Transdermal Oxybutynin: Sticking to the facts. Eur Urol 2007;51:907–14. Eur Urol 2007:52:286

Validatie van de PCA3 urinetest in een Nederlandse multicenterstudie. NTvU, 2007 Maart (2): 49-52

The time resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. .Clin Cancer Res. 2007 Feb 1;13(3):939-943

De transurethale resectie van de prostaat nader beschouwd: een kwaliteitsanalyse. NTvU, 2006 Nov (7): 201-205

Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response. J.Urol. 2006 Oct;176(4):1349-53

Evaluation of early pelvic floor physiotherapy on the duration and degree of urinary incontinence after radical retropubic prostatectomy in a non-teaching hospital. World Journal of Urology, 2005 Oct 7;:1-3

Removal of a missed polypropylene tape by a combined transurethral and transabdominal endoscopic approach. Int Urogynecol J Pelvic Floor Dysfunct. 2005 May-Jun;16(3):247-9.

The effect of biofeedback physical therapy in men with chronic pelvic pain syndrome type III. European Urology, 2005 May;47(5):607-11.

Preparaat kiezen met behulp van de SOJA-methode. Alphablokkers bij de behandeling van benigne prostaathyperplasie. Pharmaceutisch Weekblad, 139, 40, 1329-1332, 2004

Transurethral deroofing of midline prostatic cyst for subfertile men. Human Reproduction, 14(9), 2297-2300, 1999.

Testicular simple cyst and teratoma: asynchronous bilateral occurrence within the first year of life. Urology, 54, 366, 1999.

Manual derotation of the twisted spermatic cord, Brittish Journal of Urology, 83, 672-674, 1999.

Kan masturbatie moeilijker worden na circumcisie? Vademecum, 47a, 1998.

The influence of High Intensity focussed Ultrasound on the development of metastases. European Urology, 32, 91-95, 1997.

The influence of High Energy Shock Waves on the development of metastases. Ultrasound Med. Biol., 22, 339-344, 1996.

In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines. The Prostate, 26(5), 275-280, 1995.

The effects of successive High Energy Shock Wave administration on tumor blood flow. Ultrasound in Med. and Biol., 21, 243-248, 1995.

Effects of high energy shock waves on tumor blood flow and metabolism; 31P/1H/2H nuclear magnetic resonance spectroscopic studies. NMR in Biomedicine, 7, 319-326, 1994.

High energy shock waves induce an increase in the local concentration of systemically given TNF-a. J. of Urology, 152, 2164-2166, 1994.

Alterations in metabolism within the Dunning R-3327 rat prostate tumor model discriminative for different tumor biological behaviour: a 1H and 31P magnetic resonance spectroscopy study. The Prostate, 25, 19-28, 1994.

Biological effects of high energy shock waves in different tumor model systems. Forum, 4:22-31,1994. (review)

Characterization of human prostate cancer, benign prostatic hypertrophia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J. of Urology, 150, 2019-2024, 1993.

Antiproliferative effects of bacillus calmette guerin in a syngeneic rat bladder tumor model system, RBT323. J. of Urology 149, 176-182, 1993.

Neem contact met ons op

Onze specialisten

Dr. Paul Kil

Medisch Directeur en Uroloog
Paul Kil is medisch directeur en uroloog bij Andros Clinics

Prof.dr. Frans Debruyne

Oprichter Andros, Medisch Adviseur en Uroloog
Prof. dr. Frans Debruyne Uroloog Oprichter Andros Clinics

Prof.dr. Karl-Heinz Kurth

Medisch adviseur
Prof. dr. Karl Heinz Kurth Uroloog Andros Clinics

Prof.dr. Jelle Barentsz

Radioloog
Prof. dr. Jelle Barentsz Radioloog MRI Prostaat Andros Clinics

Dr. Theo de Reijke

Uroloog
Dr. Theo de Reijke Uroloog Andros Clinics

Drs. Erik Arendsen

Uroloog
Dr. Erik Arendsen Uroloog Andros Clinics

Drs. Jos Immerzeel

MRI Fusie biopsie specialist
Drs. Jos Immerzeel Prostaat MRI Fusie Biopsie Specialist Andros Clinics

Drs. Nader Naderi

Uroloog
Drs. Nader Naderi Uroloog Andros Clinics

Dr. Peter Vegt

Uroloog
Dr. Peter Vegt Uroloog Andros Clinics

Drs. Oncko van Vierssen Trip

Uroloog
Drs. Oncko van Vierssen Trip Uroloog Andros Clinics

Dr. Michiel Kiewiet de Jonge

Uroloog
Dr. Michiel Kiewiet de Jonge Uroloog Andros Clinics

Dr. Dick Janssen

Arts
Dr. Dick Janssen Arts Andros Clinics

Drs. Toine Zeegers

Uroloog
Toine Zeegers is uroloog bij Andros Clinics

Dr. Pieter Groenendijk

Uroloog

Drs. Ruud Blokker

Uroloog
Ruud Blokker

Drs. Jaap Bannenberg

Uroloog
Jaap Bannenberg is uroloog bij Andros Clinics

Drs. Puck Oude Elferink

Uroloog

Dr. Gert Dohle

Uroloog
Dr. Gert Dohle is uroloog en behandelt mannen met testosteron tekort

Dr. Patrik Zamecnik

Radioloog

Drs. Marloes van der Leest

Radioloog
Marloes van der Leest is radioloog bij Andros Clinics

Drs. Michaël Henderickx

Uroloog

Drs. Erik Roos

Uroloog

Drs. Haitze van der Veen

Uroloog
Haitze van der Veen is uroloog bij Andros Clinicsportretfoto

Drs. Pieter van den Broeke

Uroloog

Dr. Michelle Stomp – Agenant

Uroloog
Dr. Michelle Stomp - Agenant is Uroloog bij Andros Clinics

Drs. Ronald Nooter

Uroloog
Drs. Ronald Nooter is uroloog bij Andros Clinics

Drs. Jacob Brandenburg

Uroloog

Drs. Aswin Meier

Uroloog

Dr. Herman Leliefeld

Uroloog
Dr. Herman Leliefeld Andros Clinics

Dr. Magda Armeanu

Gynaecoloog

Carel Jan van der Heide

Bekkenfysiotherapeut
Carel Jan van der Heide Bekkenfysiotherapeut Andros Clinics

Jet Buschgens

Bekkenfysiotherapeut
Jet Buschgens is bekkenfysiotherapeut voor Andros Clinics